D-AP5
|
Competitive antagonist |
GluN2A |
Inhibits excitatory response. Impacts behavioral learning; blocks plasticity (LTP). |
[95,96,97] |
Riluzole
|
Competitive antagonist |
GluN1/GluN2B |
Indirect block of NMDAR. Protects from motor deficit. |
[103,104,105] |
Phencyclidine
|
Selective uncompetitive antagonist |
GluN2B/D(PCP site) |
Induces psychotic and dissociative schizophrenia-like symptoms. Impairs NMDAR neurotransmission in vivo. |
[98] |
Ketamine
|
Uncompetitive antagonist |
GluN2B/D(PCP site) |
Applied in post-synapse: inhibits excitatory pyramidal neuron in extra-synaptic GluN2B. Applied in pre-synapse: inhibits GluN2D in interneuron (induces disinhibition of Glu release in post-synapse). Up-regulates hippocampal AMPARs (GluA1/GluA2). Antidepressant. |
[100,106] |
Dizocilpine
|
Uncompetitive antagonist |
GluN2A/B/D(PCP site) |
Anticonvulsant, antidepressant. Induces memory impairments. |
[102,107] |
Ifenprodil
|
Uncompetitive antagonist |
GluN1/GluN2B(N-Terminal domain) |
Blocks GluN2B (140-fold preference for NR2B over NR2A subunits). Induces inhibition of GluN2R receptor currents. Anti-Parkinsonian effect. |
[108,109,110] |
Memantine
|
Uncompetitive antagonist |
GluN1/GluN2B |
Blocks GluN2B extra-synaptic and induces glutamatergic excitotoxicity. Used for moderate-to-severe AD. |
[111,112] |
Amantadine
|
Uncompetitive antagonist |
GluN1/GluN2B |
Blocks GluN1/GluN2B by accelerating channel closure during channel block. Used as anti-Parkinsonian drug. |
[113] |
Dextromethorphan
|
Uncompetitive antagonist |
GluN2A |
Blocks GluN2A subunit. Prevents neuronal damage and modulates pain sensation |
[114,115,116,117,118] |